Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.…
Xenon Stock Rises 12% in the Past Month on Pipeline Progress
Xenon Pharmaceuticals (NASDAQ: XENE) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 358 employees.
The shares were at 37.04 USD on 20 November 2026, down 7.2% over 52 weeks. Its 52-week range is 33.38 USD to 72.66 USD: the price is 49.0% below the high and 11.0% above the low.
Its market capitalisation is 3.64B USD.
Xenon Pharmaceuticals reports return on equity of -59.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 944.79M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 16 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 71.56 USD is 93.2% above the current price. The next earnings report is expected on 1 March 2027.